Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.

Strickler JH, Rushing CN, Niedzwiecki D, McLeod A, Altomare I, Uronis HE, Hsu SD, Zafar SY, Morse MA, Chang DZ, Wells JL, Blackwell KL, Marcom PK, Arrowood C, Bolch E, Haley S, Rangwala FA, Hatch AJ, Nixon AB, Hurwitz HI.

BMC Cancer. 2019 Nov 1;19(1):1032. doi: 10.1186/s12885-019-6234-8.

2.

Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors.

Zhu L, Narloch JL, Onkar S, Joy M, Broadwater G, Luedke C, Hall A, Kim R, Pogue-Geile K, Sammons S, Nayyar N, Chukwueke U, Brastianos PK, Anders CK, Soloff AC, Vignali DAA, Tseng GC, Emens LA, Lucas PC, Blackwell KL, Oesterreich S, Lee AV.

J Immunother Cancer. 2019 Oct 18;7(1):265. doi: 10.1186/s40425-019-0755-1.

3.

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.

Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium (TBCRC).

Clin Breast Cancer. 2019 Aug 22. pii: S1526-8209(19)30657-3. doi: 10.1016/j.clbc.2019.07.011. [Epub ahead of print]

PMID:
31558424
4.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J.

Ann Oncol. 2019 Aug 13. pii: mdz215. doi: 10.1093/annonc/mdz215. [Epub ahead of print] No abstract available.

PMID:
31407010
5.

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium.

J Clin Oncol. 2019 May 1;37(13):1081-1089. doi: 10.1200/JCO.18.01511. Epub 2019 Mar 12.

PMID:
30860945
6.

Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.

Blackwell KL, Zaman K, Qin S, Tkaczuk KHR, Campone M, Hunt D, Bryce R, Goldstein LJ; 202 Study Group.

Clin Breast Cancer. 2019 Apr;19(2):97-104.e4. doi: 10.1016/j.clbc.2018.12.011. Epub 2018 Dec 20.

PMID:
30655172
7.

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

Wu Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, Ellis C, Baselga J, Blackwell KL, Burstein HJ.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy531. [Epub ahead of print] No abstract available.

PMID:
30624581
8.

Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.

Sammons S, Kornblum NS, Blackwell KL.

Target Oncol. 2019 Feb;14(1):13. doi: 10.1007/s11523-018-0614-x.

9.

Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.

Sammons S, Kornblum NS, Blackwell KL.

Target Oncol. 2019 Feb;14(1):1-12. doi: 10.1007/s11523-018-0587-9. Erratum in: Target Oncol. 2018 Dec 8;:.

10.

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.

Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA.

Breast Cancer Res Treat. 2018 Aug;171(1):111-120. doi: 10.1007/s10549-018-4813-z. Epub 2018 May 9.

11.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J.

Ann Oncol. 2018 Jul 1;29(7):1541-1547. doi: 10.1093/annonc/mdy155.

12.

Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.

Force J, Howie LJ, Abbott SE, Bentley R, Marcom PK, Kimmick G, Westbrook K, Sammons SL, Parks M, Topping DL, Emerson R, Broadwater G, Hyslop T, Blackwell KL, Nair SK.

Clin Breast Cancer. 2018 Oct;18(5):410-417. doi: 10.1016/j.clbc.2018.02.010. Epub 2018 Feb 24.

PMID:
29615305
13.

Leptomeningeal disease: current diagnostic and therapeutic strategies.

Nayar G, Ejikeme T, Chongsathidkiet P, Elsamadicy AA, Blackwell KL, Clarke JM, Lad SP, Fecci PE.

Oncotarget. 2017 Aug 16;8(42):73312-73328. doi: 10.18632/oncotarget.20272. eCollection 2017 Sep 22. Review.

14.

Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis.

Shammas RL, Cho EH, Glener AD, Poveromo LP, Mundy LR, Greenup RA, Blackwell KL, Hollenbeck ST.

J Am Coll Surg. 2017 Dec;225(6):731-739.e1. doi: 10.1016/j.jamcollsurg.2017.08.023. Epub 2017 Oct 3.

PMID:
28985927
15.

Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.

Narloch JL, Farber SH, Sammons S, McSherry F, Herndon JE, Hoang JK, Yin FF, Sampson JH, Fecci PE, Blackwell KL, Kirkpatrick JP, Kim GJ.

Neuro Oncol. 2017 Oct 1;19(10):1391-1397. doi: 10.1093/neuonc/nox090.

16.

HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.

Sammons SL, Topping DL, Blackwell KL.

Curr Cancer Drug Targets. 2017;17(7):637-649. doi: 10.2174/1568009617666170330120452. Review.

17.

PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.

Anderson GR, Wardell SE, Cakir M, Crawford L, Leeds JC, Nussbaum DP, Shankar PS, Soderquist RS, Stein EM, Tingley JP, Winter PS, Zieser-Misenheimer EK, Alley HM, Yllanes A, Haney V, Blackwell KL, McCall SJ, McDonnell DP, Wood KC.

Sci Transl Med. 2016 Dec 14;8(369):369ra175.

18.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J.

N Engl J Med. 2016 Nov 3;375(18):1738-1748. Epub 2016 Oct 7. Erratum in: N Engl J Med. 2018 Dec 27;379(26):2582.

19.

Embracing rejection: Immunologic trends in brain metastasis.

Farber SH, Tsvankin V, Narloch JL, Kim GJ, Salama AK, Vlahovic G, Blackwell KL, Kirkpatrick JP, Fecci PE.

Oncoimmunology. 2016 Apr 11;5(7):e1172153. doi: 10.1080/2162402X.2016.1172153. eCollection 2016 Jul. Review.

20.

Increased Fiber Intake Decreases Premenopausal Breast Cancer Risk.

Harnden KK, Blackwell KL.

Pediatrics. 2016 Mar;137(3):e20154376. doi: 10.1542/peds.2015-4376. Epub 2016 Feb 1. No abstract available.

21.

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU.

J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.

22.

Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.

Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM; TRILOGY ACS Investigators.

Eur Heart J. 2016 Jan 21;37(4):412-22. doi: 10.1093/eurheartj/ehv611. Epub 2015 Dec 5.

23.

Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival.

Siamakpour-Reihani S, Owzar K, Jiang C, Scarbrough PM, Craciunescu OI, Horton JK, Dressman HK, Blackwell KL, Dewhirst MW.

Int J Hyperthermia. 2015 Jun;31(4):386-95. doi: 10.3109/02656736.2015.1016557. Epub 2015 Mar 26.

25.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E; European School of Oncology; European Society of Medical Oncology.

Breast. 2014 Oct;23(5):489-502. doi: 10.1016/j.breast.2014.08.009. Epub 2014 Sep 20. No abstract available.

26.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E.

Ann Oncol. 2014 Oct;25(10):1871-88. doi: 10.1093/annonc/mdu385. Epub 2014 Sep 18. No abstract available.

27.

Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer.

Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O'Connor B, Myerson R, Stauffer P, Hsu IC, Diederich C, Straube W, Boss MK, Boico A, Craciunescu O, Maccarini P, Needham D, Borys N, Blackwell KL, Dewhirst MW.

Int J Hyperthermia. 2014 Aug;30(5):285-94. doi: 10.3109/02656736.2014.936049.

28.

Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy.

Shelby RA, Edmond SN, Wren AA, Keefe FJ, Peppercorn JM, Marcom PK, Blackwell KL, Kimmick GG.

Support Care Cancer. 2014 Oct;22(10):2851-9. doi: 10.1007/s00520-014-2269-1. Epub 2014 May 13.

PMID:
24821365
29.

Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.

Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, Wilke LG, Masko E, Douglas PS, Dash RC, Povsic TJ, Peppercorn J, Marcom PK, Blackwell KL, Kimmick G, Turkington TG, Dewhirst MW.

Cancer Prev Res (Phila). 2013 Sep;6(9):925-37. doi: 10.1158/1940-6207.CAPR-12-0416. Epub 2013 Jul 10.

30.

How can we optimize treatment of HER2-positive metastatic breast cancer?

Hamilton EP, Blackwell KL.

Oncology (Williston Park). 2013 Mar;27(3):180, 182. No abstract available.

31.

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.

Cristofanilli M, Johnston SR, Manikhas A, Gomez HL, Gladkov O, Shao Z, Safina S, Blackwell KL, Alvarez RH, Rubin SD, Ranganathan S, Redhu S, Trudeau ME.

Breast Cancer Res Treat. 2013 Jan;137(2):471-82. doi: 10.1007/s10549-012-2369-x. Epub 2012 Dec 13.

32.

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J.

J Clin Oncol. 2012 Jul 20;30(21):2585-92. doi: 10.1200/JCO.2011.35.6725. Epub 2012 Jun 11.

PMID:
22689807
33.

Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.

Betof AS, Rabbani ZN, Hardee ME, Kim SJ, Broadwater G, Bentley RC, Snyder SA, Vujaskovic Z, Oosterwijk E, Harris LN, Horton JK, Dewhirst MW, Blackwell KL.

Br J Cancer. 2012 Feb 28;106(5):916-22. doi: 10.1038/bjc.2012.32. Epub 2012 Feb 14.

34.

Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.

Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK.

Breast Cancer Res. 2011;13(6):R125. doi: 10.1186/bcr3071. Epub 2011 Dec 1.

35.

New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.

Hamilton E, Clay TM, Blackwell KL.

Cancer Invest. 2011 Oct;29(8):533-41. doi: 10.3109/07357907.2011.605413. Epub 2011 Aug 15. Review.

PMID:
21843051
36.

Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.

Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, Kimmick GG, Favaro J, Hamilton E, Welch RA, Bacus S, Blackwell KL.

Clin Cancer Res. 2011 Sep 15;17(18):6061-70. doi: 10.1158/1078-0432.CCR-11-1071. Epub 2011 Aug 2.

37.

Safety of bevacizumab in patients with metastatic breast cancer.

Hamilton EP, Blackwell KL.

Oncology. 2011;80(5-6):314-25. doi: 10.1159/000328757. Epub 2011 Jul 19. Review.

PMID:
21778772
38.

Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS, Mao Y, He J, Wulfkuhle JD, Petricoin EF 3rd, Osada T, Yang XY, Hartman ZC, Clay TM, Blackwell KL, Lyerly HK, Spector NL.

Mol Cancer Ther. 2011 Aug;10(8):1367-74. doi: 10.1158/1535-7163.MCT-10-0991. Epub 2011 Jun 14.

39.

Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.

Gatza ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR, Chi JT.

Breast Cancer Res. 2011 Jun 7;13(3):R62. doi: 10.1186/bcr2899.

40.

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

Wu Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, Ellis C, Baselga J, Blackwell KL, Burstein HJ.

Ann Oncol. 2011 Dec;22(12):2582-90. doi: 10.1093/annonc/mdr014. Epub 2011 Mar 15.

PMID:
21406472
41.

Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?

Anders CK, Fan C, Parker JS, Carey LA, Blackwell KL, Klauber-DeMore N, Perou CM.

J Clin Oncol. 2011 Jan 1;29(1):e18-20. doi: 10.1200/JCO.2010.28.9199. Epub 2010 Nov 29. No abstract available.

42.

Hyperthermia for locally advanced breast cancer.

Zagar TM, Oleson JR, Vujaskovic Z, Dewhirst MW, Craciunescu OI, Blackwell KL, Prosnitz LR, Jones EL.

Int J Hyperthermia. 2010;26(7):618-24. doi: 10.3109/02656736.2010.501051. Review.

43.

Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data.

Zagar TM, Oleson JR, Vujaskovic Z, Dewhirst MW, Craciunescu OI, Blackwell KL, Prosnitz LR, Jones EL.

Int J Hyperthermia. 2010;26(7):612-7. doi: 10.3109/02656736.2010.487194. Review.

44.
45.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J.

J Clin Oncol. 2010 Mar 1;28(7):1124-30. doi: 10.1200/JCO.2008.21.4437. Epub 2010 Feb 1.

PMID:
20124187
46.

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Spector NL, Blackwell KL.

J Clin Oncol. 2009 Dec 1;27(34):5838-47. doi: 10.1200/JCO.2009.22.1507. Epub 2009 Nov 2. Review.

PMID:
19884552
47.

DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study.

Craciunescu OI, Blackwell KL, Jones EL, Macfall JR, Yu D, Vujaskovic Z, Wong TZ, Liotcheva V, Rosen EL, Prosnitz LR, Samulski TV, Dewhirst MW.

Int J Hyperthermia. 2009;25(6):405-15. doi: 10.1080/02656730903022700.

48.

Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae.

Westmoreland TJ, Wickramasekara SM, Guo AY, Selim AL, Winsor TS, Greenleaf AL, Blackwell KL, Olson JA Jr, Marks JR, Bennett CB.

PLoS One. 2009 Jun 8;4(6):e5830. doi: 10.1371/journal.pone.0005830.

49.

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, Forster JK, Rubin SD, Stein SH, Burstein HJ.

Ann Oncol. 2009 Jun;20(6):1026-31. doi: 10.1093/annonc/mdn759. Epub 2009 Jan 29.

PMID:
19179558
50.

Are all aromatase inhibitors alike?

Blackwell KL.

Breast Cancer Res Treat. 2008 Dec;112 Suppl 1:35-43. doi: 10.1007/s10549-008-0233-9. Epub 2008 Dec 20.

PMID:
19101793

Supplemental Content

Loading ...
Support Center